BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  BioMidwest

  Research Roundup: How Prions Replicate and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  June 24, 2021

   · 

  6 min read

   · 

  Mark Terry
• 

  Business

  Belldegrun’s Third Fund Continues “Bold Investment Strategy” with $825 Million

  Vida Ventures III will approach investments the same way its first two funds do, identifying and investing in what they believe to be transformative biomedical innovative companies.

  June 24, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  With Myeloma Drug Proving Merit in Phase I, AbbVie Scoops Up TeneoOne

  The decision to exercise the option was based on an interim analysis of the ongoing Phase I trial of TNB-383B.

  June 24, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Pharm Country

  Pfizer and AZ Prove Their COVID-19 Vaccines Can Keep Up with Delta and Kappa Variants

  The analysis showed that the Pfizer and Oxford/AstraZeneca vaccines can protect patients from being hospitalized by as much as 90 percent.

  June 24, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Aerosol Scientist: Masks, Saline Cleansers May Have Enduring Value Beyond COVID-19

  With COVID-19 ducking for cover and going into an almost full retreat across the U.S., Americans are throwing caution – and masks – to the wind. But many are still nervous, and wondering: How do we protect ourselves in this brave new normal?

  June 24, 2021

   · 

  4 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Positive Outcomes May Outweigh Failed Endpoint for Fulcrum’s FSHD Drug Losmapimod

  Fulcrum achieved what the company is calling a clinical first. Data showed that using losmapimod slowed the progression of FSHD and demonstrated improved function in patients.

  June 24, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  BioForest

  COVID-19 Origin Story Plot Thickens as Researcher Unearths Deleted Early Virus Sequences

  Last summer, claims that the deadly SARS-CoV-2 virus emerged from a virology lab in Wuhan were generally dismissed by the scientific community as right-wing conspiracy theories. A year later, the theory isn’t sounding so far-fetched.

  June 24, 2021

   · 

  5 min read

   · 

  Kate Goodwin
• 

  Business

  German Biotech Receives $17.5M to Expand in U.S.

  German biotechnology firm LEUKOCARE, which has operations in Milford, Connecticut, has announced the closing of $17.5 million financing round from New York investment firm Petrichor Healthcare Capital Management.

  June 24, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Eli Lilly Guns for Alzheimer’s Drug Approval with FDA’s Breakthrough Therapy Designation

  The company said it will file a marketing application later this year for the drug under the FDA’s accelerated approval pathway.

  June 24, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Business

  BioSpace Movers & Shakers, June 25

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

  June 24, 2021

   · 

  6 min read

   · 

  Alex Keown